- Home
- SXC vs YMAB Comparison
SXC vs YMAB Comparison
Compare SXC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- YMAB
- Stock Information
- Founded
- SXC 1960
- YMAB 2015
- Country
- SXC United States
- YMAB United States
- Employees
- SXC N/A
- YMAB N/A
- Industry
- SXC Steel/Iron Ore
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- YMAB Health Care
- Exchange
- SXC Nasdaq
- YMAB Nasdaq
- Market Cap
- SXC 722.8M
- YMAB 631.1M
- IPO Year
- SXC N/A
- YMAB 2018
- Fundamental
- Price
- SXC $12.63
- YMAB $10.10
- Analyst Decision
- SXC Strong Buy
- YMAB Strong Buy
- Analyst Count
- SXC 1
- YMAB 9
- Target Price
- SXC $13.00
- YMAB $21.56
- AVG Volume (30 Days)
- SXC 907.2K
- YMAB 274.1K
- Earning Date
- SXC 10-31-2024
- YMAB 11-08-2024
- Dividend Yield
- SXC 3.77%
- YMAB N/A
- EPS Growth
- SXC 55.48
- YMAB N/A
- EPS
- SXC 1.01
- YMAB N/A
- Revenue
- SXC $1,970,000,000.00
- YMAB $84,553,000.00
- Revenue This Year
- SXC N/A
- YMAB $10.24
- Revenue Next Year
- SXC N/A
- YMAB $20.21
- P/E Ratio
- SXC $12.42
- YMAB N/A
- Revenue Growth
- SXC N/A
- YMAB N/A
- 52 Week Low
- SXC $7.47
- YMAB $5.29
- 52 Week High
- SXC $12.81
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- SXC 78.64
- YMAB 21.95
- Support Level
- SXC $12.29
- YMAB $12.47
- Resistance Level
- SXC $12.71
- YMAB $11.11
- Average True Range (ATR)
- SXC 0.42
- YMAB 1.05
- MACD
- SXC 0.03
- YMAB -0.52
- Stochastic Oscillator
- SXC 93.75
- YMAB 4.04
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.